First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142 - Lenz, H J; Overman, M J; Cutsem, E V (J Clin Oncol, 2024)
10.1200/jco.2024.42.3_suppl.97